Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
This trial is active, not recruiting.
|Condition||unspecified adult solid tumor, protocol specific|
|Treatments||gemcitabine hydrochloride, oxaliplatin|
|Sponsor||Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|
|Start date||August 2005|
|Trial size||45 participants|
|Trial identifier||NCT00274859, CDR0000454320, EU-20571, GERCOR-SEGEMOX-S04-1, LILLY-GERCOR-SEGEMOX-S04-1, SANOFI-GERCOR-SEGEMOX-S04-1|
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine together with oxaliplatin works in treating patients with metastatic cancer who cannot receive anthracycline or taxane therapy.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Beauvais, France||C.H.G. Beauvais||no longer recruiting|
|Besancon, France||Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz||no longer recruiting|
|Boulogne Sur Mer, France||Centre Hospitalier Docteur Duchenne||no longer recruiting|
|Clermont-Ferrand, France||Centre Jean Perrin||no longer recruiting|
|Montfermeil, France||Intercommunal Hospital||no longer recruiting|
|Paris, France||Hopital Tenon||no longer recruiting|
|Paris, France||Hopital Saint Antoine||no longer recruiting|
|Reims, France||Polyclinique De Courlancy||no longer recruiting|
|Saint Cloud, France||Centre Rene Huguenin||no longer recruiting|
|Saint-Quentin, France||Centre Hospitalier de Saint-Quentin||no longer recruiting|
|Senlis, France||C.H. Senlis||no longer recruiting|
|Strasbourg, France||Centre Paul Strauss||no longer recruiting|
|Toulon - Cedex, France||Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer||no longer recruiting|
|Villejuif, France||Institut Gustave Roussy||no longer recruiting|
Objective response rate
Male or female participants at least 18 years old.
DISEASE CHARACTERISTICS: - Histologically confirmed cancer - Metastatic disease - Measurable metastatic disease ≥ 1 cm by spiral CT scan and/or cutaneous lesion ≥ 2 cm - Not a candidate for anthracycline or taxane chemotherapy - No brain metastases PATIENT CHARACTERISTICS: - ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% - Life expectancy > 12 weeks - Neutrophil count > 1,000/mm^3 - Platelet count > 100,000/mm^3 - Alkaline phosphatase < 5 times upper limit of normal (ULN) - Bilirubin < 1.5 times ULN - Creatinine < 1.5 times ULN OR creatinine clearance > 30 mL/min - SGOT and SGPT < 3 times ULN (5 times ULN if liver metastases present) - No pre-existing neuropathy - Not pregnant or nursing - No uncontrolled hypercalcemia - No familial, social, geographical, or psychological condition that would preclude study treatment - No other malignancy that is not considered cured PRIOR CONCURRENT THERAPY: - No prior chemotherapy for metastatic disease, including anthracyclines or taxanes - Prior hormonal therapy allowed
|Official title||Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes|
|Description||OBJECTIVES: Primary - Determine the objective response rate in patients with metastatic cancer not amenable to anthracycline or taxane therapy treated with gemcitabine hydrochloride and oxaliplatin. Secondary - Determine the clinical benefit and tolerability of this regimen in these patients. - Determine the progression-free and overall survival of patients treated with this regimen. OUTLINE: This is an open-label, multicenter study. Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.|
Call for more information